NOTV Quote, Financials, Valuation and Earnings

Nektar Therapeutics has a net margin of -11.96% compared to Inotiv's net margin of -486.44%. Inotiv's return on equity of -49.29% beat Nektar Therapeutics's return on equity of -201.73%.

Inotiv has a consensus price target of $5.50, signalling upside risk potential of 196.5%. On the other hand Nektar Therapeutics has an analysts' consensus of $94.83 which suggests that it could grow by 292.85%. Given that Nektar Therapeutics has higher upside potential than Inotiv, analysts believe Nektar Therapeutics is more attractive than Inotiv.

Inotiv has a beta of 3.939, which suggesting that the stock is 293.928% more volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 0.941, suggesting its less volatile than the S&P 500 by 5.928%.

Inotiv has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inotiv pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Inotiv quarterly revenues are $124.3M, which are larger than Nektar Therapeutics quarterly revenues of $10.5M. Inotiv's net income of -$14.9M is higher than Nektar Therapeutics's net income of -$50.9M. Notably, Inotiv's price-to-earnings ratio is -- while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inotiv is 0.11x versus 3.87x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Nanoviricides has a net margin of -11.96% compared to Inotiv's net margin of --. Inotiv's return on equity of -49.29% beat Nanoviricides's return on equity of --.

Inotiv has a consensus price target of $5.50, signalling upside risk potential of 196.5%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 306.25%. Given that Nanoviricides has higher upside potential than Inotiv, analysts believe Nanoviricides is more attractive than Inotiv.

Inotiv has a beta of 3.939, which suggesting that the stock is 293.928% more volatile than S&P 500. In comparison Nanoviricides has a beta of 0.882, suggesting its less volatile than the S&P 500 by 11.802%.

Inotiv has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inotiv pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

Inotiv quarterly revenues are $124.3M, which are larger than Nanoviricides quarterly revenues of --. Inotiv's net income of -$14.9M is lower than Nanoviricides's net income of -$2.2M. Notably, Inotiv's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inotiv is 0.11x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -11.96% compared to Inotiv's net margin of --. Inotiv's return on equity of -49.29% beat Oragenics's return on equity of --.

Inotiv has a consensus price target of $5.50, signalling upside risk potential of 196.5%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 2012.89%. Given that Oragenics has higher upside potential than Inotiv, analysts believe Oragenics is more attractive than Inotiv.

Inotiv has a beta of 3.939, which suggesting that the stock is 293.928% more volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

Inotiv has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inotiv pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Inotiv quarterly revenues are $124.3M, which are larger than Oragenics quarterly revenues of --. Inotiv's net income of -$14.9M is lower than Oragenics's net income of -$2.2M. Notably, Inotiv's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inotiv is 0.11x versus 0.45x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -11.96% compared to Inotiv's net margin of --. Inotiv's return on equity of -49.29% beat Theriva Biologics's return on equity of --.

Inotiv has a consensus price target of $5.50, signalling upside risk potential of 196.5%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1402.15%. Given that Theriva Biologics has higher upside potential than Inotiv, analysts believe Theriva Biologics is more attractive than Inotiv.

Inotiv has a beta of 3.939, which suggesting that the stock is 293.928% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

Inotiv has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inotiv pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Inotiv quarterly revenues are $124.3M, which are larger than Theriva Biologics quarterly revenues of --. Inotiv's net income of -$14.9M is lower than Theriva Biologics's net income of -$4.3M. Notably, Inotiv's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inotiv is 0.11x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.